When you take a multi-targeted approach* across patient types

Consider Acthar® Gel in the treatment of dermatomyositis (DM)

Patient type:
Recurring disease activity;
tough-to-treat disease;
high disease activity.



Clinical case study

Diagnosis: Dermatomyositis

Woman, aged 71 years, experiencing rash, muscle weakness, shoulder and hip pain, dyspnea, and decreased endurance for 3 years.

Case study provided by:
Sanjay Chabra, DO
Texas Arthritis Center
El Paso, TX

This case study is provided for general medical education purposes only and is not a substitute for independent clinical medical judgment. The intent of this case study is to present the experience of an individual patient, which may not represent outcomes in the overall patient population. Response to treatment may vary from patient to patient.

*Acthar Gel is indicated for certain immune-mediated and idiopathic conditions across a range of therapeutic areas and may be appropriate for multiple patient types.

INDICATION

Acthar® Gel is indicated during an exacerbation or as maintenance therapy in selected cases of dermatomyositis (polymyositis).

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Acthar is contraindicated:

- For intravenous administration
- In infants under 2 years of age who have suspected congenital infections
- With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar
- In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Please see additional Important Safety Information throughout and full Prescribing Information.

Acthar® GEL
(repository corticotropin injection) 80 U/mL

History and examination were consistent with recurring disease activity, tough-to-treat disease, and high disease activity

Clinical examination[1]

- Dermatomyositis confirmed with biopsy that revealed perifascicular atrophy
- Signs and symptoms of abrupt rash onset on hands, chest, arms, and legs, including the presence of heliotrope rash, Gottron papules, and shawl sign
- CPK level: 308 U/L
- Patient experienced muscle weakness, pain in shoulders and hips, dyspnea, and decreased endurance
- Comorbidities included depression, hypertension, seasonal allergies, and GERD*
- Aldolase level: 14.1 U/L

*Observe mood disorders as they may be aggravated, and monitor signs of gastrointestinal perforation and bleeding.

Treatment history[1]



CPK=creatine phosphokinase; GERD=gastroesophageal reflux disease; ILD=interstitial lung disease; IVIg=intravenous immunoglobulin; UTI=urinary tract infection.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment

Patient required an alternative treatment

Decision to treat with Acthar® Gel[1]

- Patient was not able to tolerate multiple disease-modifying antirheumatic drugs (DMARDs)
- Patient had ongoing active disease despite prior treatments
- Unable to taper prednisone dose

TWICE WEEKLY

Results after Acthar Gel therapy as of September 2021[1]

- Patient has received 80 units of Acthar Gel twice weekly since May 2019
  - Patient is continuing Acthar Gel therapy and is responding well
- Prednisone dose was decreased to 5 mg a day
- Improved proximal muscle strength
- Rash was significantly resolved
- Aldolase level decreased from 14.1 to 6.6 U/L
- CPK level decreased from 308 to 57 U/L
- No adverse events were observed

Clinical outcomes may not be solely attributable to Acthar Gel.

Dosage should be individualized according to the medical condition of each patient. Frequency and dose of the drug should be determined by considering the severity of the disease and the initial response of the patient.

Sudden withdrawal of Acthar Gel after prolonged use may lead to adrenal insufficiency or recurrent symptoms. It may be necessary to taper the dose and increase the injection interval to gradually discontinue the medication.

Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased.

Reference: 1. Data on file: REF-MNK05291. Mallinckrodt ARD LLC.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions (cont'd)

- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels

Please see additional Important Safety Information throughout and full Prescribing Information.

When you take a multi-targeted approach* across patient types

Consider Acthar® Gel in the treatment of dermatomyositis (DM)

Patient type:
Recurring disease activity;
tough-to-treat disease;
high disease activity.

*Acthar Gel is indicated for certain immune-mediated and idiopathic conditions across a range of therapeutic areas and may be appropriate for multiple patient types.

IMPORTANT SAFETY INFORMATION

Contraindications

Acthar is contraindicated:

- For intravenous administration
- In infants under 2 years of age who have suspected congenital infections
- With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar
- In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment
- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
- Acthar can cause gastrointestinal (GI) bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain GI disorders. Monitor for signs of perforation and bleeding
- Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated
- Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
- Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms
- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Acthar activity
- There may be an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
- Decrease in bone density may occur. Bone density should be monitored in patients on long-term therapy

Adverse Reactions

- Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased
- The most common adverse reactions for the treatment of infantile spasms (IS) are increased risk of infections, convulsions, hypertension, irritability, and pyrexia. Some patients with IS progress to other forms of seizures; IS sometimes masks these seizures, which may become visible once the clinical spasms from IS resolve

Pregnancy

- Acthar may cause fetal harm when administered to a pregnant woman

Please see full Prescribing Information.

Mallinckrodt Pharmaceuticals

Acthar® GEL
(repository corticotropin injection) 80 U/mL

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.
Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2021 Mallinckrodt. US-2101298 12/21